NeoVanc
Treatment of late onset bacterial sepsis caused by vancomycin susceptible bacteria in neonates and infants aged under three months
Funded by the European Commission’s FP7 programme, NeoVanc involves 12 European partners and is coordinated by Penta.
The aim is to develop an optimal dosing and monitoring regimen for vancomycin use in preterm neonates and infants under 3 months of age and subsequently conduct a randomised clinical trial with PK/PD targets as the primary outcome.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no: 602041. The amount of funding received in 2018 is 646.317,23 €.